Transaction #13404 · Form 4 · 0002064832-25-000026
ENANTA PHARMACEUTICALS INC · Stock award · Stock Option (right to buy)
ENANTA PHARMACEUTICALS INC · Transacted November 25, 2025 · Filed November 26, 2025
What does this filing report?
An SEC Form 4 filing for ENANTA PHARMACEUTICALS INC records a stock award involving Stock Option (right to buy) on November 25, 2025. The reported quantity was 110,000. The filing date is November 26, 2025. This is one transaction record; amounts are not allocated among any joint reporting owners.
The acquisition category describes how securities were received. It does not by itself establish a cash purchase of common stock. Read the transaction code definitionsand the original filing before interpreting the amounts.
Transaction details
- Company
- ENANTA PHARMACEUTICALS INC
- Company CIK
- 0001177648
- Security type
- Derivative
- Acquisition type
- Stock award · Code A
- Quantity acquired
- 110,000
- Reported price
- 0
- Reference value
- 0
- Currency
- Currency not specified
- Ownership
- Direct
- Holdings after transaction
- 110,000
- Ownership description
- Not reported
- SEC acceptance time
- Nov 26, 2025, 5:03 PM EST
- 10b5-1 indication
- Not indicated
Reference value is reported quantity × reported price. It is not a confirmed cash payment or an estimate of a derivative's economic value. A missing currency is not assumed to be USD.
Reporting owners
- Or Yat Sun ↗
Chief Scientific Officer
CIK 0001571212
These are the reporting owners named in the filing. Quantities and amounts are not allocated among co-reporters. Roles reflect this filing, not a current profile.
Company listings
This transaction is not mapped to a specific company listing.
Derivative terms
- Underlying security
- Common Stock
- Underlying quantity
- 110,000
- Conversion / exercise price
- 13.66
- Exercise date
- Not reported
- Expiration date
- November 25, 2035
Filing footnotes & remarks
- F1
- Such option will become exercisable (subject to the optionholder's continued employment) quarterly in substantially equal installments (any fractional shares to be cumulated and to become exercisable at the end of the earliest succeeding quarterly period in which a whole share equivalent is accumulated) over four years from the date of grant (November 25, 2025).
Footnotes are reproduced as plain text from the current source filing. For the full context, read the original SEC filing.
This record was updated Eastern Time. This is the stored record update time, not the transaction date. Report a correction.